Abstract
Chronic respiratory diseases include chronic obstructive pulmonary disease (COPD), pulmonary tuberculosis, idiopathic pulmonary fibrosis (IPF), cystic fibrosis, asthma, and lung cancers. These diseases have high mortality and morbidity rates. These persistent disorders are fatal in majority of the cases, and in advance stages, the damage done is non-repairable, almost null. There is still a significant need to carry out extensive research studies to establish liposomes as the most preferred drug carrier, especially for respiratory system related disorders. Therefor they seem to hold promise with their tremendous potential of targeting the desired site in the studies done so far.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Agee J (2007) 81 an approach to the child. Gen Pract 56:844
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-Koshki K (2013) Liposome: classification, preparation, and applications. Nanoscale Res Lett 8:102
Alpes H, Allmann K, Plattner H, Reichert J, Rick R, Schulz S (1986) Formation of large Unilamellar vesicles using alkyl Maltoside detergents. Biochim Biophys Acta Biomembr 862:294–302
Anderson CF, Grimmett ME, Domalewski CJ, Cui H (2020) Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 12:E1586
Atrooz O (2011) Effects of alkylresorcinolic lipids obtained from acetonic extract of Jordanian wheat grains on liposome properties. Int J Biol Chem 5:314–321
Bahadori M, Mohammadi F (2012) Nanomedicine for respiratory diseases. Tanaffos 11:18
Baker KE, Bonvini SJ, Donovan C, Foong RE, Han B, Jha A, Shaifta Y, Smit M, Johnson JR, Moir LM (2014) Novel drug targets for asthma and Copd: lessons learned from in vitro and in vivo models. Pulm Pharmacol Ther 29:181–198
Barenholz YC (2012) Doxil®—The first Fda-approved nano-drug: lessons learned. J Control Release 160:117–134
Barker KF (1999) Antibiotic resistance: a current perspective. Br J Clin Pharmacol 48:109
Batzri S, Korn ED (1973) Single bilayer liposomes prepared without sonication. Biochim Biophys Acta Biomembr 298:1015–1019
Baughman R (1999) The lung in the immunocompromised patient. Respiration 66:95–109
Bendas ER, Tadros MI (2007) Enhanced transdermal delivery of salbutamol sulfate via Ethosomes. AAPS PharmSciTech 8:213
Benech R-O, Kheadr E, Laridi R, Lacroix C, Fliss I (2002) Inhibition of Listeria Innocua in Cheddar cheese by addition of Nisin Z in liposomes or by in situ production in mixed culture. Appl Environ Microbiol 68:3683–3690
Berne RM, Levy MN, Koeppen BM (2008) Berne & Levy physiology. Elsevier, Brasil
Bhardwaj A, Kumar L, Narang R, Murthy R (2013) Development and characterization of ligand-appended liposomes for multiple drug therapy for pulmonary tuberculosis. Artific Cells Nanomed Biotechnol 41:52–59
Burgess DS (1999) Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 115:19s–23s
Burns DM (2000) Primary prevention, smoking, and smoking cessation: implications for future trends in lung cancer prevention. Cancer 89:2506–2509
Cagle PT, Allen TC, Olsen RJ (2013) Lung cancer biomarkers: present status and future developments. Arch Pathol Lab Med 137:1191–1198
Champion JA, Mitragotri S (2009) Shape induced inhibition of phagocytosis of polymer particles. Pharm Res 26:244–249
Chen X, Huang W, Wong BC, Yin L, Wong YF, Xu M, Yang Z (2012) Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int J Nanomedicine 7:1139
Cruz AA (2007) Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. World Health Organization, Geneva
D’alonzo GE, Dantzker DR (1983) Respiratory failure, mechanisms of abnormal gas exchange, and oxygen delivery. Med Clin N Am 67:557–571
Darquenne C, Fleming JS, Katz I, Martin AR, Schroeter J, Usmani OS, Venegas J, Schmid O (2016) Bridging the gap between science and clinical efficacy: physiology, imaging, and modeling of aerosols in the lung. J Aerosol Med Pulm Drug Deliv 29:107–126
De Backer L, Cerrada A, Pérez-Gil J, De Smedt SC, Raemdonck K (2015) Bio-inspired materials in drug delivery: exploring the role of pulmonary surfactant in Sirna inhalation therapy. J Control Release 220:642–650
Deamer D, Bangham A (1976) Large volume liposomes by an ether vaporization method. Biochim Biophys Acta Biomembr 443:629–634
Dharmadhikari AS, Mphahlele M, Venter K, Stoltz A, Mathebula R, Masotla T, Van Der Walt M, Pagano M, Jensen P, Nardell E (2014) Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 18:1019–1025
Drake R, Vogl AW, Mitchell AW (2009) Gray’s anatomy for students E-book. Elsevier Health Sciences TW
Durham AL, Caramori G, Chung KF, Adcock IM (2016) Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. Transl Res 167:192–203
Dye C, Williams BG (2010) The population dynamics and control of tuberculosis. Science 328:856–861
Escombe AR, Moore DA, Gilman RH, Pan W, Navincopa M, Ticona E, MartÃnez C, Caviedes L, Sheen P, Gonzalez A (2008) The infectiousness of tuberculosis patients Coinfected with HIV. PLoS Med 5:E188
Fujita Y, Takeshita F, Kuwano K, Ochiya T (2013) Rnai therapeutic platforms for lung diseases. Pharmaceuticals 6:223–250
Gabizon A, Goren D, Cohen R, Barenholz Y (1998) Development of liposomal anthracyclines: from basics to clinical applications. J Control Release 53:275–279
Ganong WF (1995) Review of medical physiology. Mcgraw-Hill, Lange, USA
Gao L, Tao Y, Zhang L, Jin Q (2010) Vitamin D receptor genetic polymorphisms and tuberculosis: updated systematic review and Meta-analysis. Int J Tuberc Lung Dis 14:15–23
Greene KE, Peters JI (1994) Pathophysiology of acute respiratory failure. Clin Chest Med 15:1–12
Halbert R, Natoli J, Gano A, Badamgarav E, Buist AS, Mannino D (2006) Global burden of Copd: systematic review and meta-analysis. Eur Respir J 28:523–532
Henning A, Schneider M, Nafee N, Muijs L, Rytting E, Wang X, Kissel T, Grafahrend D, Klee D, Lehr C-M (2010) Influence of particle size and material properties on mucociliary clearance from the airways. J Aerosol Med Pulm Drug Deliv 23:233–241
Hofheinz R-D, Gnad-Vogt SU, Beyer U, Hochhaus A (2005) Liposomal encapsulated anti-cancer drugs. Anti Cancer Drugs 16:691–707
Holgate ST, Polosa R (2006) The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 368:780–793
Hua S (2013) Targeting sites of inflammation: intercellular adhesion molecule-1 as a target for novel inflammatory therapies. Front Pharmacol 4:127
Jain V, Bhardwaj A (2019) Pneumonia pathology. Statpearls [internet]. Statpearls Publishing, Treasure Island (FL)
Janssens J-P, Pache J-C, Nicod L (1999) Physiological changes in respiratory function associated with ageing. Eur Respir J 13:197–205
Jin J, Hu K, Zhou Y, Li W (2017) Clinical utility of the modified Glasgow prognostic score in lung cancer: a meta-analysis. PLoS One 12:E0184412
Johnson L (1998) Essential medical physiology. Lippincott, Philadelphia, PA, pp 468–472
Johnston MJ, Semple SC, Klimuk SK, Ansell S, Maurer N, Cullis PR (2007) Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta Biomembr 1768:1121–1127
Karn PR, Vanić Z, Pepić I, Škalko-Basnet N (2011) Mucoadhesive liposomal delivery systems: the choice of coating material. Drug Dev Ind Pharm 37:482–488
Kataria S, Sandhu P, Bilandi A, Akanksha M, Kapoor B (2011) Stealth liposomes: a review. Int J Res Ayurveda Pharm 2
Kelly HW, Murphy S (1992) Beta-adrenergic agonists for acute, severe asthma. Ann Pharmacother 26:81–91
Kelly C, Jefferies C, Cryan S-A (2011) Targeted liposomal drug delivery to monocytes and macrophages. J Drug Del 2011
Kleinnijenhuis J, Joosten LA, Van De Veerdonk FL, Savage N, Van Crevel R, Kullberg BJ, Van Der Ven A, Ottenhoff TH, Dinarello CA, Van Der Meer JW (2009) Transcriptional and Inflammasome-mediated pathways for the induction of Il-1β production by Mycobacterium Tuberculosis. Eur J Immunol 39:1914–1922
Kocher F, Hilbe W, Seeber A, Pircher A, Schmid T, Greil R, Auberger J, Nevinny-Stickel M, Sterlacci W, Tzankov A (2015) Longitudinal analysis of 2293 Nsclc patients: a comprehensive study from the Tyrol registry. Lung Cancer 87:193–200
Kumana CR, Yuen KY (1994) Parenteral aminoglycoside therapy. Drugs 47:902–913
Lai SK, Suk JS, Pace A, Wang Y-Y, Yang M, Mert O, Chen J, Kim J, Hanes J (2011) Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus. Biomaterials 32:6285–6290
Lee W-H, Loo C-Y, Traini D, Young PM (2015) Nano-and micro-based inhaled drug delivery systems for targeting alveolar macrophages. Expert Opin Drug Deliv 12:1009–1026
Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar J-S, Squire J (2013) Molecular testing guideline for selection of lung Cancer patients for Egfr and Alk tyrosine kinase inhibitors: guideline from the college of American pathologists, international association for the study of lung cancer, and association for molecular pathology. J Thorac Oncol 8:823–859
Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K (2018) Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of American pathologists, the international association for the study of lung cancer, and the association for molecular pathology. J Thorac Oncol 13:323–358
Lombry C, Edwards DA, Préat V, Vanbever R (2004) Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. Am J Phys Lung Cell Mol Phys 286:L1002–L1008
Mälkki-Laine L, Purra K, Kähkönen K, Tammilehto S (1995) Decomposition of salbutamol in aqueous solutions. Ii. The effect of buffer species, Ph, buffer concentration and antioxidants. Int J Pharm 117:189–195
Maslan J, Mims JW (2014) What is asthma? Pathophysiology, demographics, and health care costs. Otolaryngol Clin N Am 47:13–22
Masoli M, Fabian D, Holt S, Beasley R, Program GIFA (2004) The global burden of asthma: executive summary of the Gina dissemination committee report. Allergy 59:469–478
Mayer LD, Bally MB, Hope MJ, Cullis PR (1986) Techniques for encapsulating bioactive agents into liposomes. Chem Phys Lipids 40:333–345
Møller H, Jørgensen N, Forman D (1995) Trends in incidence of testicular cancer in boys and adolescent men. Int J Cancer 61:761–764
Moller W, Felten K, Sommerer K, Scheuch G, Meyer G, Meyer P, Haussinger K, Kreyling WG (2008) Deposition, retention, and translocation of ultrafine particles from the central airways and lung periphery. Am J Respir Crit Care Med 177:426–432
Moore KL, Dalley AF (2018) Clinically oriented anatomy. Wolters Kluwer India Pvt Ltd., India
Mosgoeller W, Prassl R, Zimmer A (2012) Nanoparticle-mediated treatment of pulmonary arterial hypertension. Methods in Enzymology 508:325–354
Mozafari MR (2005) Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett 10:711
Nizet T, Broeders M, Folgering HTM (2004) Tremor side effects of salbutamol, quantified by a laser pointer technique. Respir Med 98:844–850
Nunn A, Phillips PP, Abubakar I (2013) Treatment of pulmonary tuberculosis. Curr Opin Pulm Med 19:273–279
Oyen WJ, Boerman OC, Storm G, Bloois LV, Koenders EB, Claessens RA, Perenboom RM, Crommelin DJ, Van Der Meer JW, Corstens FH (1996) Detecting infection and inflammation with technetium-99m-labeled stealth liposomes. J Nucl Med 37(8):1392–1397
Pocock G, Richards CD, Richards DA (2013) Human physiology. Oxford University Press, Oxford
Raesch SS, Tenzer S, Storck W, Rurainski A, Selzer D, Ruge CA, Perez-Gil J, Schaefer UF, Lehr C-M (2015) Proteomic and Lipidomic analysis of nanoparticle corona upon contact with lung surfactant reveals differences in protein, but not lipid composition. ACS Nano 9:11872–11885
Ramakrishnan L (2012) Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol 12:352–366
Ratemi E, Sultana Shaik A, Al Faraj A, Halwani R (2016) Alternative approaches for the treatment of airway diseases: focus on nanoparticle medicine. Clin Exp Allergy 46:1033–1042
Restrepo RD (2007) Inhaled adrenergics and anticholinergics in obstructive lung disease: do they enhance mucociliary clearance? Respir Care 52:1159–1175
Riaz M (1996) Liposomes preparation methods. Pak J Pharm Sci 9:65–77
Robertson JD, Ward JR, Avila-Olias M, Battaglia G, Renshaw SA (2017) Targeting neutrophilic inflammation using polymersome-mediated cellular delivery. J Immunol 198:3596–3604
Ruppert C, Schmidt R, Grimminger F, Suzuki Y, Seeger W, Lehr C-M, Günther A (2002) Chemical coupling of a monoclonal antisurfactant protein-B antibody to human Urokinase for targeting surfactant-incorporating alveolar fibrin. Bioconjug Chem 13:804–811
Sáenz B, Hernandez-Pando R, Fragoso G, Bottasso O, Cárdenas G (2013) The dual face of central nervous system tuberculosis: a new Janus Bifrons? Tuberculosis 93:130–135
Sahoo SK, Labhasetwar V (2003) Nanotech approaches to drug delivery and imaging. Drug Discov Today 8:1112–1120
Sahoo B, Devi KSP, Banerjee R, Maiti TK, Pramanik P, Dhara D (2013) Thermal and Ph responsive polymer-tethered multifunctional magnetic nanoparticles for targeted delivery of anticancer drug. ACS Appl Mater Interfaces 5:3884–3893
Samet JM (2018) Lung cancer, smoking, and obesity: it’s complicated. Oxford University Press, Oxford
Schieren H, Rudolph S, Finkelstein M, Coleman P, Weissmann G (1978) Comparison of large Unilamellar vesicles prepared by a petroleum ether vaporization method with multilamellar vesicles: Esr, diffusion and entrapment analyses. Biochim Biophys Acta Gen Sub 542:137–153
Schiffelers RM, Bakker-Woudenberg IA, Snijders SV, Storm G (1999) Localization of sterically stabilized liposomes in Klebsiella Pneumoniae-infected rat lung tissue: influence of liposome characteristics. Biochim Biophys Acta Biomembr 1421:329–339
Schiffelers RM, Bakker-Woudenberg IA, Storm G (2000) Localization of sterically stabilized liposomes in experimental rat Klebsiella Pneumoniae pneumonia: dependence on circulation kinetics and presence of poly (ethylene) glycol coating. Biochim Biophys Acta Biomembr 1468:253–261
Schiffelers RM, Storm G, Marian T, Bakker-Woudenberg IA (2001) Therapeutic efficacy of liposome-encapsulated gentamicin in rat Klebsiella Pneumoniae pneumonia in relation to impaired host defense and low bacterial susceptibility to gentamicin. Antimicrob Agents Chemother 45:464–470
Schmidt-Rohr K (2020) Oxygen is the high-energy molecule powering complex multicellular life: fundamental corrections to traditional bioenergetics. Acs Omega 5:2221–2233
Shaheen SM, Shakil Ahmed F, Hossen MN, Ahmed M, Amran MS, Ul-Islam M (2006) Liposome as a carrier for advanced drug delivery. Pak J Biol Sci 9:1181–1191
Sharma A, Sharma US (1997) Liposomes in drug delivery: progress and limitations. Int J Pharm 154:123–140
Shehata T, Ogawara K-I, Higaki K, Kimura T (2008) Prolongation of residence time of liposome by surface-modification with mixture of hydrophilic polymers. Int J Pharm 359:272–279
Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30
Smola M, Vandamme T, Sokolowski A (2008) Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int J Nanomedicine 3:1
Song H, Geng H, Ruan J, Wang K, Bao C, Wang J, Peng X, Zhang X, Cui D (2011) Development of polysorbate 80/phospholipid mixed micellar formation for docetaxel and assessment of its in vivo distribution in animal models. Nanoscale Res Lett 6:354
Sullivan JT, Young EF, Mccann JR, Braunstein M (2012) The Mycobacterium Tuberculosis Seca2 system subverts phagosome maturation to promote growth in macrophages. Infect Immun 80:996–1006
Sweetman SC (2009) Martindale: the complete drug reference. Pharmaceutical Press, London
Todoroff J, Vanbever R (2011) Fate of nanomedicines in the lungs. Curr Opin Colloid Interface Sci 16:246–254
Tortora GJ, Derrickson BH (2018) Principles of anatomy and physiology. John Wiley & Sons Inc., USA
Tu J, Inthavong K, Ahmadi G (2012) Computational fluid and particle dynamics in the human respiratory system. Springer Science & Business Media, Germany
Van Crevel R, Ottenhoff TH, Van Der Meer JW (2002) Innate immunity to Mycobacterium Tuberculosis. Clin Microbiol Rev 15:294–309
Wagner A, Vorauer-Uhl K (2011) Liposome technology for industrial purposes. J Drug Deliv 2011
Wan C, Allen T, Cullis P (2014) Lipid nanoparticle delivery systems for Sirna-based therapeutics. Drug Deliv Transl Res 4:74–83
Wasthi V, Goins B, Klipper R, Loredo R, Korvick D, Phillips WT (1998) Imaging experimental osteomyelitis using radiolabeled liposomes. J Nucl Med 39:1089–1094
Wheeler CJ, Felgner PL, Tsai YJ, Marshall J, Sukhu L, Doh SG, Hartikka J, Nietupski J, Manthorpe M, Nichols M (1996) A novel cationic lipid greatly enhances plasmid Dna delivery and expression in mouse lung. Proc Natl Acad Sci 93:11454–11459
Williams SG, Schmidt DK, Redd SC, Storms W (2003) Key clinical activities for quality asthma care. Recommendations of the national asthma education and prevention program. MMWR Recomm Rep 52:1–8
Witts L (1962) Year book of medicine. Br Med J 1:1188
World Health Organization (2013) Global tuberculosis report 2013. World Health Organization
Ww B (2001) Lemanske Rf Jr. Asthma. N Engl J Med 344:350–362
Zhang Y (2011) Relationship between size and function of natural substance particles. Nano Biomed Eng 3
Zhang T, Chen Y, Ge Y, Hu Y, Li M, Jin Y (2018) Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers. Acta Pharm Sin B 8:440–448
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Kulkarni, M.P., Kiran, P.S.S., Kumar, R. (2022). Liposomal Drug Delivery: Therapeutic Applications in Chronic Respiratory Diseases. In: Chellappan, D.K., Pabreja, K., Faiyazuddin, M. (eds) Advanced Drug Delivery Strategies for Targeting Chronic Inflammatory Lung Diseases . Springer, Singapore. https://doi.org/10.1007/978-981-16-4392-7_20
Download citation
DOI: https://doi.org/10.1007/978-981-16-4392-7_20
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-4391-0
Online ISBN: 978-981-16-4392-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)